Nordea: Novo’s revenue will increase markedly
Pan-Nordic bank Nordea sees revenue growth for Novo Nordisk that is significantly higher than the company’s own estimates in the current fiscal year, according to a new analysis in which the bank also offers estimates for Novo’s obesity sales.
BY STEFAN SINGH KAILAY
Novo Nordisk can look forward to a remarkable year as far as sales of products goes, says Nordea.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
New accolades for Novo Nordisk
For abonnenter
Novo Nordisk abandons diversity targets
For abonnenter
Here is how much Novo has made with Rebien at the helm
For abonnenter
